Antidepressants are functional antagonists at the serotonin type 3 (5-HT3) receptor

Molecular Psychiatry

Volumn 8, Issue 12, 2003, Pages 994-1007

  Eisensamer, B ^a,b   Rammes, G ^a   Gimpl, G ^c   Shapa, M ^b   Ferrari, U ^a   Hapfelmeier, G ^d   Bondy, B ^b   Parsons, C ^e   Gilling, K ^e   Zieglgansberger W ^a   Holsboer, F ^a   Rupprecht, R ^a,b,f  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e MERZ PHARMACEUTICALS GMBH   (Germany)

^f LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

5 HT3 receptor; Antidepressant drug; Calcium signal; Ligand gated ion channel; Noncompetitive antagonism; Patch clamp

Indexed keywords

10,11 DIHYDROCARBAMAZEPINE; 3 (5 METHYL 1H IMIDAZOL 4 YL) 1 (1 METHYL 1H INDOL 3 YL) 1 PROPANONE; ANTIDEPRESSANT AGENT; CALCIUM ION; CARBAMAZEPINE; DESIPRAMINE; DIBENZOSUBERANE; FLUOXETINE; IMINODIBENZYL DERIVATIVE; IMIPRAMINE; MIRTAZAPINE; MOCLOBEMIDE; NORADRENALIN UPTAKE INHIBITOR; REBOXETINE; SEROTONIN 3 RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SODIUM ION; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; TRITIUM; UNCLASSIFIED DRUG;

ANIMAL CELL; ANISOTROPY; ARTICLE; CALCIUM CELL LEVEL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; EMBRYO; HUMAN; HUMAN CELL; KIDNEY CELL; NEUROBLASTOMA CELL; NONHUMAN; NORADRENERGIC SYSTEM; PATCH CLAMP; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; RAT; SEROTONINERGIC SYSTEM; SODIUM CURRENT; STEADY STATE; VOLTAGE CLAMP;

ANIMALS; ANTIDEPRESSIVE AGENTS; CALCIUM; CELL LINE; CELL LINE, TUMOR; HIPPOCAMPUS; HUMANS; KIDNEY; MEMBRANE POTENTIALS; NEUROBLASTOMA; NEURONS; RATS; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN;

EID: 10744226824     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4001314     Document Type: Article

References (47)

1. Pacher P, Kohegyi E, Kecskemeti V, Frust S. Current trends in the development of new antidepressants. Curr Med Chem 2001; 8: 89-100.
2. Blakely RD. Physiological genomics of antidepressant targets: keeping the periphery in mind. J Neurosci 2001; 21: 8319-8323.
3. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997; 54: 597-606.
4. Holsboer F, Barden N. Antidepressants and hypothalamic pituitary adrenocortical regulation. Endocrine Rev 1996; 17: 187-205.
5. Kent JM. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 2000; 355: 911-918.
6. Frazer A. Serotonergic and noradrenergic reuptake inhibitors: prediction of clinical effects from in vitro potencies. J Clin Psychiatry 2001; 62: 16-23.
7. 3 receptor-mediated current by the selective serotonin uptake inhibitor, fluoxetine. Neurosci Lett 1994; 173: 210-212.
8. 3 receptor by nicotine, cocaine, and fluoxetine investigated by rapid chemical kinetic techniques. Biochemistry 2001; 40: 8419-8429.
9. 3 receptor, a serotonin-gated ion channel. Science 1991; 254: 432-437.
10. 3B subunit is a major determinant of serotonin-receptor function. Nature 1999; 397: 359-363.
11. 3B receptor subunit. J Biol Chem 1999; 274: 30799-30810.
12. 3 receptor, a serotonin-gated ion channel. Nature 1987; 330: 746-748.
13. 3 receptor in rat brain using radioligand binding. Proc Natl Acad Sci USA 1993; 90: 1430-1443.
14. 3 receptors in rat amygdala. Neuron 1992; 8: 199-203.
15. Gralla RJ, Hri LMPSE, Squillant AE, Kelsen DP, Braun DW, Bordin LA et al. Antiemetic efficacy of high dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 1991; 305: 905-909.
16. Kazemi-Kjellberg F, Henzi I, Tramer M. Treatment of established postoperative nausea and vomiting: a quantitative systematic review. BMC Anesthesiol 2001; 1: 2.
17. 3 receptor antagonist and its applications in CNS-related disorders. CNS Drug Rev 2001; 7: 199-213.
18. 3 receptor antagonists, ondansetron and WAY 100289, in the elevated plus-maze test of anxiety of mice. Psychopharmacology 1995; 117: 306-312.
19. 3 receptor agonist attenuates the action of antidepressants in the forced swim test in rats. Brain Res 1998; 786: 189-193.
20. 3 receptor antagonists. Drugs 1997; 53: 20-39.
21. Warburton AC, Cole JC, Tredwell JM. Antagonism of amphetamine-induced disruption of latent inhibition in rats by haloperidol and ondansetron: implications for a possible antipsychotic action of ondansetron. Psychopharmacology 1994; 114: 657-664.
22. Zoldan J, Friedberg G, Goldberg-Stern H, Melamed E. Ondansetron for hallucinosis in advanced Parkinson's disease. Lancet 1993; 341: 562-563.
23. Wetzel CHR, Hermann B, Behl C, Pestel E, Rammes G, Ziegelgänsberger W et al. Functional antagonism of gonadal steroids at the 5-hydroxytryptamine type 3 receptor. Mol Endocrinol 1998; 12: 1441-1451.
24. A receptor function. Trends Pharmacol Sci 1995; 16: 295-303.
25. Rupprecht R, Holsboer F. Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci 1999; 22: 410-416.
26. 3 receptor cDNA and its splice variants from guinea pig. Mol Pharmacol 1998; 53: 202-212.
27. 2+ ] in mononuclear blood cells from demented patients and healthy controls. Eur Arch Psychiatry Clin Neurosci 1994; 243: 224-228.
28. Munson PJ, Rodbard D. LIGAND: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 1980; 107: 263-270.
29. Gimpl G, Fahrenholz F. Human oxytocin receptors in cholesterol-rich vs. cholesterol-poor microdomains of the plasma membrane. Eur J Biochem 2000; 267: 2483-2497.
30. 3 receptors in rat nodose ganglion neurones. Br J Pharmacol 1994; 112: 741-744.
31. Bufler J, Wilhelm R, Parnas H, Franke C, Dudel J. Open channel and competitive block of the embryonic form of the nicotinic receptor of mouse myotubes by (+)-tubocurarine. J Physiol 1996; 495: 83-95.
32. Rammes G, Rupprecht R, Ferrari U, Zieglgänsberger W, Parsons CG. The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT3 receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neurosci Lett 2001; 306: 81-84.
33. 3A). J Physiol 1998; 507: 653-665.
34. Bliss AVP, Collingridge GL. A synaptic model of memory-long-term potentiation in the hippocampus. Nature 1993; 361: 31-39.
35. 2+ permeability of cloned and native 5-hydroxytryptamine type 3 receptors. Mol Pharmacol 1994; 46: 1120-1128.
36. Wilson GG, Karlin A. The location of the gate in the acetylcholine receptor channel. Neuron 1998; 20: 1269-1281.
37. Bertrand D, Galzi JL, Devillers-Thiery A, Bertrand S, Changeux JP. Mutations at two distinct sites within the channel domain M2 alter calcium permeability of neuronal A7 nicotinic receptor. Neurobiology 1993; 90: 6971-6975.
38. +-ATPase activity. Mol Pharmacol 1993; 44: 129-141.
39. Melzacka M, Nocon H. Effect of imipramine on the membrane anisotropy and on the phospholipid methylation in the central nervous system of the rat. J Pharm Pharmacol 1990; 43: 564-568.
40. Lejoyeux M, Daveloose D, Mazière JC, Adès J, Viret J. A spin label study of the membrane effect of various psychoactive drugs in human erythrocytes. Life Sci 1992; 52: PL-7-PL-11.
41. Sanganahalli BG, Joshi PG, Joshi NB. Differential effects of tricyclic antidepressant drugs on membrane dynamics - a fluorescence spectroscopic study. Life Sci 2000; 68: 81-90.
42. Blanton MP, Xie Y, Dangott LJ, Cohen JB. The steroid promegestone is a noncompetitive antagonist of the Torpedo nicotinic acetylcholine receptor that interacts with the lipid-protein interface. Mol Pharmacol 1999; 55: 269-278.
43. Barrantes FJ, Antollini SS, Bouzat C, Garbus I, Massol RH. Nongenomic effects of steroids on the nicotinic acetylcholine receptor. Kidney Int 2000; 57: 1382-1389.
44. Weigmann H, Härtter S, Bagli M, Hiemke C. Steady state concentrations of clomipramine and its major metabolite desmethylclomipramine in rat brain and serum after oral administration of clomipramine. Eur Neuropsychopharmacol 2000; 10: 401-405.
45. Uhr M, Sleekler T, Yassouridis A, Holsboer F. Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to Mdrla P-glycoprotein gene disruption. Neuropsychopharmacology 2000; 22: 380-387.
46. Bolo NR, Hodé Y, Nédélec JF, Lainé E, Wagner G, Macher JP. Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. Neuropsychopharmacology 2000; 23: 428-438.
47. Henry ME, Moore C, Kaufmann M, Michelson D, Schmidt M, Stoddard E et al. Brain kinetics of paroxetine and fluoxetine on the third day of placebo substitution: a fluorine MRS study. Am J Psychiatry 2000; 157: 1506-1508.